Vifor Pharma


Broad-based growth across divisions; FY19 guidance upgraded

09/08/19 -"In H1, sales snowballed by 22.2% led by robust growth momentum across key drugs – Ferinject, Mircera, Velphoro and Veltassa. Growth in EBITDA was even higher (+32.6%) on the back of strong ..."

Pages
57
Language
English
Published on
09/08/19
You may also be interested by these reports :
29/05/20
A few months after our endorsement in March 2019, Genmab (Reduce, Denmark) made a big splash on Nasdaq with one of the biggest IPOs in biotech ...

28/05/20
... or ~€-300bn, this is the latest estimate of the potential negative impact on GDP of the pandemic by the German Economic Institute. The crucial ...

08/05/20
Given that the subcutaneous formulation of the lynchpin drug, Darzalex, is now approved by the US FDA, we have increased our estimates for the drug. ...

30/04/20
We have increased our FY20 earnings on the back of a better than expected favourable product mix (higher sales contribution from the Dupixent and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO